46 results on '"Rolland, Anne-Sophie"'
Search Results
2. Development and validation of the DBS-PS (Deep Brain Stimulation-Perception Scale): Assessing parkinsonian patients' expectations to prevent post-operative disappointment?
- Author
-
Meyer, Mylène, Spitz, Elisabeth, Colnat-Coulbois, Sophie, Benatru, Isabelle, Guehl, Dominique, Hainque, Elodie, Rolland, Anne-Sophie, Corvol, Jean-Christophe, Devilliers, Hervé, Schwan, Raymund, and Devos, David
- Published
- 2024
- Full Text
- View/download PDF
3. Could the motor unit number index be an early prognostic biomarker for amyotrophic lateral sclerosis?
- Author
-
Grapperon, Aude-Marie, Harlay, Vincent, Boucekine, Mohamed, Devos, David, Rolland, Anne-Sophie, Desnuelle, Claude, Delmont, Emilien, Verschueren, Annie, and Attarian, Shahram
- Published
- 2024
- Full Text
- View/download PDF
4. Caffeine consumption outcomes on amyotrophic lateral sclerosis disease progression and cognition
- Author
-
Huin, Vincent, Blum, David, Delforge, Violette, Cailliau, Emeline, Djeziri, Sofia, Dujardin, Kathy, Genet, Alexandre, Viard, Romain, Attarian, Shahram, Bruneteau, Gaelle, Cassereau, Julien, Genestet, Steeve, Kaminsky, Anne-Laure, Soriani, Marie-Hélène, Lefilliatre, Mathilde, Couratier, Philippe, Pittion-Vouyovitch, Sophie, Esselin, Florence, De La Cruz, Elisa, Guy, Nathalie, Kolev, Ivan, Corcia, Philippe, Cintas, Pascal, Desnuelle, Claude, Buée, Luc, Danel-Brunaud, Véronique, Devos, David, and Rolland, Anne-Sophie
- Published
- 2024
- Full Text
- View/download PDF
5. Therapeutic inhibition of ferroptosis in neurodegenerative disease
- Author
-
Ryan, Sean K., Ugalde, Cathryn L., Rolland, Anne-Sophie, Skidmore, John, Devos, David, and Hammond, Timothy R.
- Published
- 2023
- Full Text
- View/download PDF
6. SARS-CoV-2 detection using a nanobody-functionalized voltammetric device
- Author
-
Pagneux, Quentin, Roussel, Alain, Saada, Hiba, Cambillau, Christian, Amigues, Béatrice, Delauzun, Vincent, Engelmann, Ilka, Alidjinou, Enagnon Kazali, Ogiez, Judith, Rolland, Anne Sophie, Faure, Emmanuel, Poissy, Julien, Duhamel, Alain, Boukherroub, Rabah, Devos, David, and Szunerits, Sabine
- Published
- 2022
- Full Text
- View/download PDF
7. Personality assessment with Temperament and Character Inventory in Parkinson's disease
- Author
-
Moreau, Caroline, Defebvre, Pr Luc, Carriere, Dr Nicolas, Grolez, Dr Guillaume, Baille, Dr Guillaume, Kreisler, Dr, Jean-Pierre Pruvo, Pr, Leclerc, Pr, Lopes, Dr Renaud, Viard, Dr Romain, Kuchcinski, Dr Gregory, Dumont, Mr Julien, Dujardin, Pr Kathy, Delliaux, Mme M., Brion, Mrs M., Touzet, Dr Gustavo, Reyns, Pr Nicolas, Delval, Pr Arnaud, Santraine, Mrs Valerie, Pleuvret, Mrs Marie, Dautrevaux, Mrs Nolwen, Laugeais, Mr Victor, Ouk, Thavarak, Potey, Camille, Leclercq, Celine, Gers, Elise, Corvol, Jean-Christophe, Marie-Vidailhet, Hainque, Elodie, Welter, Marie-Laure, Lacomblez, Lucette, Grabli, David, Roze, Emmanuel, Worbe, Yulia, Delorme, Cécile, You, Hana, Ihle, Jonas, Guimeraes-Costa, Raquel, Cormier-Dequaire, Florence, Méneret, Aurélie, Hartmann, Andréas, Mariani, Louise-Laure, Lehericy, Stéphane, Czernecki, Virginie, Pineau, Fanny, Bozon, Frédérique, Huiban, Camille, Benchetrit, Eve, Karachi, Carine, Navarro, Soledad, Cornu, Philippe, Welaratne, Arlette, Dongmo-Kenfack, Carole, Mantisi, Lise, Jarry, Nathalie, Aix, Sophie, Lefort, Carine, Rouaud, Dr Tiphaine, Damier, Pr Philippe, Derkinderen, Pr Pascal, Anne-Gaelle Corbille, Dr, Calvier-Auffray, Dr Elisabeth, Rocher, Mrs Laetitia, Anne-Laure Deruet, Mrs, Sylvie, Dr Raoul, Vincent, Dr Roualdes, Le Dily Séverine, Mrs, Marques, Dr Ana, Debilly, Dr Berangere, Durif, Pr Franck, Derost, Dr Philippe, Beal, Dr Charlotte, Chassain, Carine, Delaby, Laure, Vidal, Tiphaine, Jacques Lemaire, Pr Jean, Rieu, Isabelle, Durand, Elodie, Eusebio, Pr Alexandre, Jean-Philippe Azulay, Pr, Witjas, Dr Tatiana, Fluchère, Dr Frédérique, Grimaldi, Dr Stephan, Girard, Pr Nadine, Delfini, Marie, Carron, Dr Romain, Regis, Pr Jean, Spatola, Dr Giorgio, Magnaudet, Camille, Solène, Dr Ansquer, Isabelle, Dr Benatru, Olivier, Dr Colin, Houeto Jl, Pr, Remy, Pr Guillevin, Anne, Mrs Fradet, Manssouri, Mrs Anziza, Sophie, Mrs Blondeau, Philippe, Dr Richard, Philippe, Dr Cam, Philippe, Dr Page, Benoit, Pr Bataille, Emilie, Mrs Rabois, Annie, Mrs Guillemain, Sophie, Dr Drapier, Leh, Dr Frédérique, Bonnet, Dr Alexandre, Vérin, Pr Marc, Jean-Christophe Ferré, Dr, François Houvenaghel, Mr Jean, Haegelen, Pr Claire, Kestens, Mrs Francoise, Ory, Mrs Solenn, Burbaud, Pr Pierre, Damon-Perriere, Dr Nathalie, Meissner, Pr Wassilios, Tison, Pr Francois, Bannier, Dr Stéphanie, Krim, Dr Elsa, Guehl, Pr Dominique, Molinier-Blossier, Sandrine, Ollivier, Morgan, Lacoste, Marion, Auzou, Nicolas, Bonnet, Marie, Cuny, Pr Emmanuel, Engelhardt, Dr Julien, Branchard, Olivier, Huet, Clotilde, Blanchard, Julie, Olivier, Pr Rascol, Brefel Courbon, Dr Christine, Ory Magne, Dr Fabienne, Simonetta Moreau, Dr Marion, Arbus, Pr Christophe, Bonneville, Pr Fabrice, Albert Lotterie, Dr Jean, Sarrail, Marion, Scotto d’Apollonia, Charlotte, Chaynes, Pr Patrick, Caire, Pr François, Harroch, Estelle, Maltete, Pr David, Lefaucheur, Dr Romain, Fetter, Dr Damien, Magne, Dr Nicolas, Bioux, Mrs Sandrine, Loubeyre, Mrs Maud, Bliaux, Mrs Evangéline, Pouliquen, Mrs Dorothée, Derrey, Pr Stéphane, Vernon, Mrs Linda, Ziegler, Dr Frédéric, Anheim, Mathieu, Lagha-Boukbiza, Ouhaid, Tranchant, Christine, Gebus, Odile, Montaut, Solveig, Kremer, S., Longato, Nadine, Phillips, Clélie, Voirin, Jimmy, Santin, Marie des Neiges, Chaussemy, Dominique, Mengin, Dr Amaury, Giordana, Dr Caroline, Marsé, Dr Claire, Mondot, Lydiane, Giordana, Bruno, Kardous, Robin, Bailet, Bernadette, Joly, Héloise, Fontaine, Denys, Leplus, Dr Aurélie, Faustini, Amélie, Ferrier, Vanessa, Krystkowiak, Pr Pierre, Tir, Dr Mélissa, Jean-Marc Constans, Pr, Wannepain, Sandrine, Seling, Audrey, Lefranc, Dr Michel, Blin, Stéphanie, Schuler, Béatrice, Thobois, Pr Stephane, Danaila, Dr Teodor, Laurencin, Dr Chloe, Berthezene, Pr Yves, Ameli, Dr Roxana, Klinger, Helene, Polo, Dr Gustavo, Mertens, Patrick, Nunes, A., Metereau, Elise, Hopes, Dr Lucie, Frismand, Dr Solène, Schmitt, Dr Emmanuelle, Meyer, Mrs Mylène, Dillier, Mrs Céline, Colnat, Pr Sophie, Chatelain, Mrs Anne, Philippe Brandel, Dr Jean, Hubsch, Dr Cécile, Karsenti, Dr Patte, Lebouteux, Dr Marie, Ziegler, Dr Marc, Delmaire, Dr Christine, Savatowky, Dr Julien, Vrillac, Mrs Juliette, Nakache, Mrs Claire, D'Hardemare, Dr Vincent, Belamri, Mr Lhaouas, Mesnage, Dr Valérie, Bonnet, Dr Cécilia, Correa Lino, Dr Jarbas, Jr., Decrocq, Dr Camille, Boulin, Dr Anne, Barre, Mrs Inès, Manouvrier, Mrs Jordane, Gardel, Dr Bérénice, Jarraya, Pr Béchir, Ziz, Mrs Catherine, Prette, Mrs Lydie, Douzane, Mr Hassen, Gay, David, Bonicel, Robin, El Mountassir, Fouzia, Fischer, Clara, Mangin, Jean-François, Chupin, Marie, Cointepas, Yann, Accart, Bertrand, Gelé, Patrick, Fievet, Florine, Chabel, Matthieu, Derenaucourt, Virginie, Facon, Loïc, Njosse, Yanick Tchantchou, Deplanque, Dominique, Duhamel, Alain, Djemmane, Lynda, Duflot, Florence, Boussac, Mathilde, Arbus, Christophe, Colin, Olivier, Laurencin, Chloé, Eusebio, Alexandre, Corvol, Jean Christophe, Versace, Nathalie, Rascol, Olivier, Rousseau, Vanessa, Ory-Magne, Fabienne, Fabbri, Margherita, Rolland, Anne-Sophie, Jarraya, Béchir, Maltête, David, Drapier, Sophie, Marques, Ana-Raquel, Wirth, Thomas, Meyer, Mylène, Tir, Mélissa, Rouaud, Tiphaine, Devos, David, and Brefel-Courbon, Christine
- Published
- 2022
- Full Text
- View/download PDF
8. The Use of Image Guided Programming to Improve Deep Brain Stimulation Workflows with Directional Leads in Parkinson’s Disease
- Author
-
Rolland, Anne-Sophie, primary, Touzet, Gustavo, additional, Carriere, Nicolas, additional, Mutez, Eugenie, additional, Kreisler, Alexandre, additional, Simonin, Clemence, additional, Kuchcinski, Gregory, additional, Chalhoub, Najib, additional, Pruvo, Jean-Pierre, additional, Defebvre, Luc, additional, Reyns, Nicolas, additional, Devos, David, additional, and Moreau, Caroline, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Texture-based markers from structural imaging correlate with motor handicap in Parkinson’s disease
- Author
-
Betrouni, Nacim, Moreau, Caroline, Rolland, Anne-Sophie, Carrière, Nicolas, Chupin, Marie, Kuchcinski, Gregory, Lopes, Renaud, Viard, Romain, Defebvre, Luc, and Devos, David
- Published
- 2021
- Full Text
- View/download PDF
10. Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations
- Author
-
Benchetrit, Eve, Delaby, Laure, Berthet, Deborah, Danjou, Fabrice, Vidaihlet, Marie, Krack, Paul, Pelissier, Pierre, Morand, Dominique, Delaigue, Christine, Barun, Nadia, Anheim, Mathieu, Pleuvret, Marie, Destée, Alain, Defebvre, Luc, Moreau, Caroline, Simonin, Clémence, Ryckewaert, Gilles, Kreisler, Alexandre, Mutez, Eugénie, Carrière, Nicolas, Hopes, Lucie, Tard, Céline, Grolez, Guillaume, Dujardin, Kathy, Pecheux, Nathalie, Delliaux, Marie, Rolland, Anne-Sophie, Broussolle, Emmanuel, Laurencin, Chloè, Tison, François, Burbaud, Pierre, Mangone, Graziella, Bekadar, Samir, Cormier-Dequaire, Florence, Tahiri, Khadija, Welaratne, Arlette, Czernecki, Virginie, Pineau, Fanny, Karachi, Carine, Castrioto, Anna, Durif, Frank, Tranchant, Christine, Devos, David, Thobois, Stéphane, Meissner, Wassilios G, Navarro, Maria Soledad, Cornu, Philippe, Lesage, Suzanne, Brice, Alexis, Welter, Marie Laure, and Corvol, Jean-Christophe
- Published
- 2020
- Full Text
- View/download PDF
11. Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson's disease.
- Author
-
Béreau, Matthieu, Kibleur, Astrid, Servant, Mathieu, Clément, Gautier, Dujardin, Kathy, Rolland, Anne-Sophie, Wirth, Thomas, Lagha-Boukbiza, Ouhaid, Voirin, Jimmy, Santin, Marie des Neiges, Hainque, Elodie, Grabli, David, Comte, Alexandre, Drapier, Sophie, Durif, Franck, Marques, Ana, Eusebio, Alexandre, Azulay, Jean-Philippe, Giordana, Caroline, and Houeto, Jean-Luc
- Subjects
APATHY ,SUBTHALAMIC nucleus ,PARKINSON'S disease ,DEEP brain stimulation ,EXECUTIVE function ,EPISODIC memory ,MOTIVATION (Psychology) - Abstract
Postoperative apathy is a frequent symptom in Parkinson's disease patients who have undergone bilateral deep brain stimulation of the subthalamic nucleus. Two main hypotheses for postoperative apathy have been suggested: (i) dopaminergic withdrawal syndrome relative to postoperative dopaminergic drug tapering; and (ii) direct effect of chronic stimulation of the subthalamic nucleus. The primary objective of our study was to describe preoperative and 1-year postoperative apathy in Parkinson's disease patients who underwent chronic bilateral deep brain stimulation of the subthalamic nucleus. We also aimed to identify factors associated with 1-year postoperative apathy considering: (i) preoperative clinical phenotype; (ii) dopaminergic drug management; and (iii) volume of tissue activated within the subthalamic nucleus and the surrounding structures. We investigated a prospective clinical cohort of 367 patients before and 1 year after chronic bilateral deep brain stimulation of the subthalamic nucleus. We assessed apathy using the Lille Apathy Rating Scale and carried out a systematic evaluation of motor, cognitive and behavioural signs. We modelled the volume of tissue activated in 161 patients using the Lead-DBS toolbox and analysed overlaps within motor, cognitive and limbic parts of the subthalamic nucleus. Of the 367 patients, 94 (25.6%) exhibited 1-year postoperative apathy: 67 (18.2%) with ' de novo apathy' and 27 (7.4%) with 'sustained apathy'. We observed disappearance of preoperative apathy in 22 (6.0%) patients, who were classified as having 'reversed apathy'. Lastly, 251 (68.4%) patients had neither preoperative nor postoperative apathy and were classified as having 'no apathy'. We identified preoperative apathy score [odds ratio (OR) 1.16; 95% confidence interval (CI) 1.10, 1.22; P < 0.001], preoperative episodic memory free recall score (OR 0.93; 95% CI 0.88, 0.97; P = 0.003) and 1-year postoperative motor responsiveness (OR 0.98; 95% CI 0.96, 0.99; P = 0.009) as the main factors associated with postoperative apathy. We showed that neither dopaminergic dose reduction nor subthalamic stimulation were associated with postoperative apathy. Patients with 'sustained apathy' had poorer preoperative fronto-striatal cognitive status and a higher preoperative action initiation apathy subscore. In these patients, apathy score and cognitive status worsened postoperatively despite significantly lower reduction in dopamine agonists (P = 0.023), suggesting cognitive dopa-resistant apathy. Patients with 'reversed apathy' benefited from the psychostimulant effect of chronic stimulation of the limbic part of the left subthalamic nucleus (P = 0.043), suggesting motivational apathy. Our results highlight the need for careful preoperative assessment of motivational and cognitive components of apathy as well as executive functions in order to better prevent or manage postoperative apathy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. The Use of Image Guided Programming to Improve Deep Brain Stimulation Workflows with Directional Leads in Parkinson's Disease.
- Author
-
Rolland, Anne-Sophie, Touzet, Gustavo, Carriere, Nicolas, Mutez, Eugenie, Kreisler, Alexandre, Simonin, Clemence, Kuchcinski, Gregory, Chalhoub, Najib, Pruvo, Jean-Pierre, Defebvre, Luc, Reyns, Nicolas, Devos, David, and Moreau, Caroline
- Subjects
- *
DEEP brain stimulation , *PARKINSON'S disease , *BRAIN stimulation , *SUBTHALAMIC nucleus , *CLINICAL medicine - Abstract
Background: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a preferred treatment for parkinsonian patients with severe motor fluctuations. Proper targeting of the STN sensorimotor segment appears to be a crucial factor for success of the procedure. The recent introduction of directional leads theoretically increases stimulation specificity in this challenging area but also requires more precise stimulation parameters. Objective: We investigated whether commercially available software for image guided programming (IGP) could maximize the benefits of DBS by informing the clinical standard care (CSC) and improving programming workflows. Methods: We prospectively analyzed 32 consecutive parkinsonian patients implanted with bilateral directional leads in the STN. Double blind stimulation parameters determined by CSC and IGP were assessed and compared at three months post-surgery. IGP was used to adjust stimulation parameters if further clinical refinement was required. Overall clinical efficacy was evaluated one-year post-surgery. Results: We observed 78% concordance between the two electrode levels selected by the blinded IGP prediction and CSC assessments. In 64% of cases requiring refinement, IGP improved clinical efficacy or reduced mild side effects, predominantly by facilitating the use of directional stimulation (93% of refinements). Conclusions: The use of image guided programming saves time and assists clinical refinement, which may be beneficial to the clinical standard care for STN-DBS and further improve the outcomes of DBS for PD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Trial of Deferiprone in Parkinson’s Disease
- Author
-
Devos, David, Labreuche, Julien, Dušek, Petr, Post, Bart, Bloem, Bastiaan R, Berg, Daniela, Maetzler, Walter, Otto, Markus, Habert, Marie-Odile, Lehericy, Stéphane, Ferreira, Joaquim, Dodel, Richard, Rascol, Olivier, Tranchant, Christine, Eusebio, Alexandre, Thobois, Stéphane, Marques, Ana-Raquel, Meissner, Wassilios G, Ory-Magne, Fabienne, Walter, Uwe, de Bie, Rob M A, Gago, Miguel, Vilas, Dolores, Corvol, Jean-Christophe, Kulisevsky, Jaime, Januario, Cristina, Coelho, Miguel V S, Behnke, Stefanie, Worth, Paul, Seppi, Klaus, Ouk, Thavarak, Potey, Camille, Leclercq, Céline, Viard, Romain, Duhamel, Alain, Kuchcinski, Gregory, Lopes, Renaud, Pruvo, Jean-Pierre, Pigny, Pascal, Garçon, Guillaume, Simonin, Ophélie, Carpentier, Jessica, Rolland, Anne-Sophie, Nyholm, Dag, Scherfler, Christoph, Guyon Delannoy, Pauline, Mangin, Jean-François, Chupin, Marie, Bordet, Régis, Dexter, David T, Fradette, Caroline, Spino, Michael, Tricta, Fernando, Ayton, Scott, Bush, Ashley I, Devedjian, Jean-Christophe, Poewe, Werner, Duce, James A, Cabantchik, Ioav, Defebvre, Luc, Deplanque, Dominique, Moreau, Caroline, Group, FAIRPARK-II Study, Compta, Yaroslau, Pavese, Nicola, Růžička, Evžen, Basenau, Sandra, Beliveau, Vincent, Benchetrit, Eve, Best, Laura, Bloem, Bas, Bonicel, Robin, Boraud, T., Bordet, Regis, Bouca, Raquel, Bourdain, Frédéric, Bouzas, Jimena, Brefel-Courbon, Christine, Bubenheim, Michael, Burn, David, Bush, Ashley I, Cabantchik, Ioav, Calvas, Fabienne, Cámara, Ana, Campolongo, Antonia, Carrière, Nicolas, Chaigneau, Véronique, Matthieu, Collin, Compta, Yaroslau, Connelly, John, Cormier-Dequaire, Florence, Cranston, Amy, Dean, Rory, De Marzi, Roberto, Degos, Bertrand, Demotes, Jacques, Dellapina, Estelle, Deplanque, Dominique, Devedjian, Jean-Christophe, Devos, David, Dexter, David, Dodel, Richard, Dongmo, Carole, Duce, James, Duhamel, Alain, Dupouy, Julia, Dusek, Petr, El Mountassir, Fouzia, Eyvrard, Frédéric, Fernández, Manel, Ferreira, Joaquim, Forni, Gian Luca, Foster, Victoria, Foubert-Samier, Alexandra, Fradette, Caroline, Fréville, Laëtitia, Galitzky, Monique, Gaudebout, Cecile, Gelé, Patrick, Giladi, Nir, Grabli, David, Gleixner, Franck, Grolez, Guillaume, Guyon, Pauline, Habert, Marie-Odile, Harroch, Estelle, Hartmann, Andreas, Hirsch, Denise, Hisbergues, Michael, Hobert, Markus A, Hopfner, Franziska, Jurado, Camille, Kaiser, Andreas, Keen, Gill, Klaus, Seppi, Kouassi, Nadège, Labreuch, Julien, Lacomblez, Lucette, Lagha Boukbiza, Ouhaid, Lanthaler, Barbara, Lechatellier, Gilles, Le Forestier, Nadine, Lehmann, Fred, Lloret, Teresa, Le Naour, J., Le Toullec, Benjamin, Locatelli, Maxime, Löhle, Matthias, Lomeña, F., Longato, Nadine, Lützen, Ulf, McNichol, Ann, Maetzler, Corina, Maetzler, Walter, Mahlknecht, Philipp, Mangone, Graziella, Marín-Lahoz, Juan, Mariani, Louise-Laure, Marques, Ana, Matei, Mihaela, Matthias, Löhle, Maucourt Bacchi, Emilie, Meissner, Wassilios, Michon, Amelie, Moreau, Caroline, Nardocci, Nardo, Nosal, Florence, Nyholm, Dag, Oeckl, Patrick, Oravska, Irena, Ory, Fabienne, Otto, Markus, Ouk, Thavarak, Pagonabarraga, Javier, Pascual-Sedano, Berta, Peball, Marina, Phillips, Clélie, Pineau, Fanny, Planellas, Lluís, Pop-Ilieva, Chiesi, Rabier, Aurélie, Olivier, D., Riedel, Christian, Rodrigues, Maura, Roullet-Solignac, Isabelle, Rose, Christian, Rozova, Anna, Růžička, Evžen, Salis, Alexandra, Schäffer, Eva, Scherfler, Christoph, Schiefermeier, Natalia, Seppi, Klaus, Smagghe, Delphine, Silva, Tânia, Silva, Pedro, Socha, Julie, Souyris, Corinne, Spampinato, Umberto, Spino, Michael, Steel, Alison, Sweta, Bajaj, Thalamas, Claire, Teodor, Danaila, Teresa, Anna, Tison, François, Tolosa, Eduardo, Tricta, Fernando, Trifirò Trifirò, Gianluca, Vidailhet, Marie, Wang, Yi, Werkmann, Mario, Yilmas, Rezzak, You, Hana, Zeuner, Kirsten, Defebvre, Luc, Rascol, Olivier, Tranchant, Christine, Eusebio, Alexandre, Thobois, Stéphane, Corvol, Jean-Christophe, Durif, Franck, Meissner, Wassilos, Yaroslau, Compta, Vilas, Dolores, Kulisevsky, Jaime, Poewe, Werner, Ruzicka, Evzen, Gago, Miguel, Januario, Cristina, Vilhena Soares Coelho, Miguel, Berg, Daniela, Behnke, Stefanie, Walter, Uwe, Worth, Paul, Pavese, Nicola, Post, Bart, de Bie, Rob M A, Abbruzzese, Giovanni, Accart, Bertrand, Allain, Marie-Anne, Anheim, Mathieu, Ardigo, Diego, Aracil-Bolaños, Ignacio, Baba, Paul, Bakker, Martijn, Balzer-Geldsetzer, Monika, Bargalló, Núria, Barone, Paolo, Neurology, ANS - Neurodegeneration, and APH - Aging & Later Life
- Subjects
administration & dosage [Deferiprone] ,Dopamine ,Dopamine Agents ,Medizin ,Administration, Oral ,Levodopa ,Antiparkinson Agents ,therapeutic use [Dopamine Agents] ,therapeutic use [Deferiprone] ,Deferiprone ,metabolism [Iron] ,adverse effects [Deferiprone] ,Geriatrics/Aging ,Parkinson Disease ,General Medicine ,Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3] ,Hematology/Oncology ,chemistry [Substantia Nigra] ,adverse effects [Dopamine Agents] ,Disease Progression ,administration & dosage [Dopamine Agents] ,physiopathology [Parkinson Disease] ,adverse effects [Iron Chelating Agents] ,Neutropenia ,analysis [Iron] ,administration & dosage [Antiparkinson Agents] ,Iron ,metabolism [Parkinson Disease] ,Neurology/Neurosurgery ,therapeutic use [Levodopa] ,Iron Chelating Agents ,pharmacology [Iron Chelating Agents] ,Double-Blind Method ,adverse effects [Antiparkinson Agents] ,Genetics ,diagnostic imaging [Substantia Nigra] ,metabolism [Substantia Nigra] ,Humans ,ddc:610 ,diagnostic imaging [Brain] ,therapeutic use [Antiparkinson Agents] ,Brain Chemistry ,pharmacology [Antiparkinson Agents] ,therapeutic use [Iron Chelating Agents] ,Hematology/Oncology General ,chemically induced [Neutropenia] ,pharmacology [Deferiprone] ,drug therapy [Parkinson Disease] ,administration & dosage [Iron Chelating Agents] ,Geriatrics/Aging General ,pharmacology [Dopamine Agents] ,drug effects [Substantia Nigra] ,Neuroscience - Abstract
Contains fulltext : 287484.pdf (Publisher’s version ) (Open Access) BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear. METHODS: We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa. Participants were assigned (in a 1:1 ratio) to receive oral deferiprone at a dose of 15 mg per kilogram of body weight twice daily or matched placebo for 36 weeks. Dopaminergic therapy was withheld unless deemed necessary for symptom control. The primary outcome was the change in the total score on the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS; range, 0 to 260, with higher scores indicating more severe impairment) at 36 weeks. Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. RESULTS: A total of 372 participants were enrolled; 186 were assigned to receive deferiprone and 186 to receive placebo. Progression of symptoms led to the initiation of dopaminergic therapy in 22.0% of the participants in the deferiprone group and 2.7% of those in the placebo group. The mean MDS-UPDRS total score at baseline was 34.3 in the deferiprone group and 33.2 in the placebo group and increased (worsened) by 15.6 points and 6.3 points, respectively (difference, 9.3 points; 95% confidence interval, 6.3 to 12.2; P
- Published
- 2022
14. Can Dopamine Responsiveness Be Predicted in Parkinson’s Disease Without an Acute Administration Test?
- Author
-
Betrouni, Nacim, Moreau, Caroline, Rolland, Anne-Sophie, Carrière, Nicolas, Viard, Romain, Lopes, Renaud, Kuchcinski, Gregory, Eusebio, Alexandre, Thobois, Stephane, Hainque, Elodie, Hubsch, Cecile, Rascol, Olivier, Brefel, Christine, Drapier, Sophie, Giordana, Caroline, Durif, Franck, Maltête, David, Guehl, Dominique, Hopes, Lucie, Rouaud, Tiphaine, Jarraya, Bechir, Benatru, Isabelle, Tranchant, Christine, Tir, Melissa, Chupin, Marie, Bardinet, Eric, Defebvre, Luc, Corvol, Jean-Christophe, Devos, David, Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), École des Hautes Études en Santé Publique [EHESP] (EHESP), CHU Lille, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Plateformes Lilloises en Biologie et Santé - UAR 2014 - US 41 (PLBS), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), CHU Marseille, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Service de Neurologie [CHU Nice], Hôpital Pasteur [Nice] (CHU)-Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Normandie Université (NU), CHU Bordeaux [Bordeaux], Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Amiens-Picardie, Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), and Université de Picardie Jules Verne (UPJV)
- Subjects
Antiparkinson Agents ,Levodopa ,Cellular and Molecular Neuroscience ,Dopamine ,[SCCO.NEUR]Cognitive science/Neuroscience ,Humans ,Parkinson Disease ,Neurology (clinical) ,Magnetic Resonance Imaging - Abstract
Background: Dopamine responsiveness (dopa-sensitivity) is an important parameter in the management of patients with Parkinson’s disease (PD). For quantification of this parameter, patients undergo a challenge test with acute Levodopa administration after drug withdrawal, which may lead to patient discomfort and use of significant resources. Objective: Our objective was to develop a predictive model combining clinical scores and imaging. Methods: 350 patients, recruited by 13 specialist French centers and considered for deep brain stimulation, underwent an acute L-dopa challenge (dopa-sensitivity > 30%), full assessment, and MRI investigations, including T1w and R2* images. Data were randomly divided into a learning base from 10 centers and data from the remaining centers for testing. A machine selection approach was applied to choose the optimal variables and these were then used in regression modeling. Complexity of the modelling was incremental, while the first model considered only clinical variables, the subsequent included imaging features. The performances were evaluated by comparing the estimated values and actual values Results: Whatever the model, the variables age, sex, disease duration, and motor scores were selected as contributors. The first model used them and the coefficients of determination (R2) was 0.60 for the testing set and 0.69 in the learning set (p
- Published
- 2022
15. Analyse volumétrique du tronc cérébral : prédictibilité de la fonction respiratoire et bulbaire dans la sclérose latérale amyotrophique
- Author
-
Khamaysa, Mohammed, primary, Lefort, Muriel, additional, Pélégrini-Issac, Mélanie, additional, Lackmy-Vallée, Alexandra, additional, Preuilh, Arnaud, additional, Devos, David, additional, Rolland, Anne-Sophie, additional, Marchand-Pauvert, Veronique, additional, Querin, Giorgia, additional, and Pradat, Pierre-François, additional
- Published
- 2023
- Full Text
- View/download PDF
16. Author Correction: A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis
- Author
-
Devos, David, Moreau, Caroline, Kyheng, Maeva, Garçon, Guillaume, Rolland, Anne Sophie, Blasco, Hélène, Gelé, Patrick, Lenglet, T. Timothée, Veyrat-Durebex, C., Corcia, Philippe, Dutheil, Mary, Bede, Peter, Jeromin, Andreas, Oeckl, Patrick, Otto, Markus, Meininger, Vincent, Danel-Brunaud, Véronique, Devedjian, Jean-Christophe, Duce, James A., and Pradat, Pierre François
- Published
- 2020
- Full Text
- View/download PDF
17. A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis
- Author
-
Devos, David, Moreau, Caroline, Kyheng, Maeva, Garçon, Guillaume, Rolland, Anne Sophie, Blasco, Hélène, Gelé, Patrick, Timothée Lenglet, T., Veyrat-Durebex, C., Corcia, Philippe, Dutheil, Mary, Bede, Peter, Jeromin, Andreas, Oeckl, Patrick, Otto, Markus, Meininger, Vincent, Danel-Brunaud, Véronique, Devedjian, Jean-christophe, Duce, James A., and Pradat, Pierre François
- Published
- 2019
- Full Text
- View/download PDF
18. Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson’s Disease (PSYCHO-STIM II)
- Author
-
Boussac, Mathilde, Arbus, Christophe, Klinger, Helene, Eusebio, Alexandre, Hainque, Elodie, Christophe Corvol, Jean, Rascol, Olivier, Rousseau, Vanessa, Harroch, Estelle, D’apollonia, Charlotte Scotto, Croiset, Aurélie, Ory-Magne, Fabienne, de Barros, Amaury, Fabbri, Margherita, Moreau, Caroline, Rolland, Anne-Sophie, Benatru, Isabelle, Anheim, Mathieu, Marques, Ana-Raquel, Maltête, David, Drapier, Sophie, Jarraya, Béchir, Hubsch, Cécile, Guehl, Dominique, Meyer, Mylène, Rouaud, Tiphaine, Giordana, Bruno, Tir, Mélissa, Devos, David, Brefel-Courbon, Christine, Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hospices Civils de Lyon, Departement de Neurologie (HCL), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Neurosciences de la Timone (INT), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre d’Excellence en Maladies Neurodégénératives (NeuroToul), CIC - Biotherapie - Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Etudes et de Recherches en Psychopathologie et Psychologie de la Santé (CERPPS), Université de Toulouse (UT)-Université de Toulouse (UT)-Toulouse Mind & Brain Institut (TMBI), Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre for Integrative Biology - CBI (Inserm U964 - CNRS UMR7104 - IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Neuroimagerie cognitive - Psychologie cognitive expérimentale (UNICOG-U992), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Bordeaux [Bordeaux], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Centre Hospitalier Universitaire de Nice (CHU Nice), Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), The study was funded by the France Parkinson charity and French Ministry of Health (PHRC national 2012). This is an ancillary study to Protocol ID: 2013-A00193-42, ClinicalTrials.gov:NCT02360683., Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], CHU Toulouse [Toulouse], Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Lille Neurosciences & Cognition - U 1172 (LilNCog (ex-JPARC)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Saclay (COmUE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Neurosciences Fonctionnelles et Pathologies, Université de Picardie Jules Verne (UPJV)-Université Lille 2 - Faculté de Médecine -Université Charles de Gaulle - Lille 3, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Saclay (COmUE)
- Subjects
Deep Brain Stimulation ,[SDV]Life Sciences [q-bio] ,novelty seeking ,Parkinson Disease ,DBS-STN ,humanities ,030227 psychiatry ,nervous system diseases ,Cohort Studies ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,surgical procedures, operative ,nervous system ,quality of life ,Subthalamic Nucleus ,Parkinson’s disease ,Humans ,Cooperativeness ,Neurology (clinical) ,therapeutics ,030217 neurology & neurosurgery ,Personality - Abstract
International audience; BACKGROUND: Deep brain stimulation of the sub-thalamic nucleus (DBS-STN) reduces symptoms in Parkinson’s disease (PD) patients with motor fluctuations. However, some patients may not feel ameliorated afterwards, despite an objective motor improvement. It is thus important to find new predictors of patients’ quality of life (QoL) amelioration after DBS-STN. We hypothesized that personality dimensions might affect QoL after DBS-STN. OBJECTIVE: To evaluate associations between personality dimensions and QoL improvement one year after DBS-STN. METHODS: DBS-STN-PD patients (n = 303) having answered the "Temperament and Character Inventory" (TCI) before surgery and the PDQ-39 before and one year after surgery were included, from the cohort study PREDI-STIM. Linear regression models were used to evaluate associations between TCI dimensions and change in PDQ-39 scores after DBS-STN. RESULTS: Novelty Seeking and Cooperativeness scores before surgery were positively associated with PDQ-39 scores improvement after DBS-STN (FDR-adjusted p < 0.01). Moreover, paradoxically unimproved patients with deterioration of their PDQ-39 scores after DBS-STN despite improvement of their MDS-UPDRS-IV scores had lower Cooperativeness scores, while paradoxically improved patients with amelioration of their PDQ-39 scores despite deterioration of their MDS-UPDRS-IV scores had higher Reward Dependence scores. CONCLUSION: Some presurgical personality dimensions were significantly associated with QoL amelioration and discrepancy between motor state and QoL changes after DBS-STN in PD. Educational programs before DBS-STN should take in account patient personality dimensions to better deal with their expectations.
- Published
- 2022
19. Sensing of COVID-19 spike protein in nasopharyngeal samples using a portable surface plasmon resonance diagnostic system
- Author
-
Saada, Hiba, primary, Pagneux, Quentin, additional, Wei, James, additional, Live, Ludovic, additional, Roussel, Alain, additional, Dogliani, Alexis, additional, Die Morini, Lycia, additional, Engelmann, Ilka, additional, Alidjinou, Enagnon Kazali, additional, Rolland, Anne Sophie, additional, Faure, Emmanuel, additional, Poissy, Julien, additional, Labreuche, Julien, additional, Lee, Gil, additional, Li, Peng, additional, Curran, Gerard, additional, Jawhari, Anass, additional, Yunda, Jhonny A., additional, Melinte, Sorin, additional, Legay, Axel, additional, Gala, Jean-Luc, additional, Devos, David, additional, Boukherroub, Rabah, additional, and Szunerits, Sabine, additional
- Published
- 2022
- Full Text
- View/download PDF
20. Heterogeneity of PD-MCI in Candidates to Subthalamic Deep Brain Stimulation: Associated Cortical and Subcortical Modifications.
- Author
-
Devignes, Quentin, Daoudi, Sami, Viard, Romain, Lopes, Renaud, Betrouni, Nacim, Kuchcinski, Gregory, Rolland, Anne-Sophie, Moreau, Caroline, Defebvre, Luc, Bardinet, Eric, Bonnet, Marie, Brefel-Courbon, Christine, Delmaire, Christine, El Mountassir, Fouzia, Fluchère, Frédérique, Fradet, Anne, Giordana, Caroline, Hainque, Elodie, Houvenaghel, Jean-François, and Jarraya, Béchir
- Subjects
DEEP brain stimulation ,SUBTHALAMIC nucleus ,CAUDATE nucleus ,CEREBRAL cortical thinning ,MILD cognitive impairment ,PARKINSON'S disease - Abstract
Background: Parkinson's disease mild cognitive impairment (PD-MCI) is frequent and heterogenous. There is no consensus about its influence on subthalamic deep brain stimulation (STN-DBS) outcomes. Objective: To determine the prevalence of PD-MCI and its subtypes in candidates to STN-DBS. Secondarily, we sought to identify MRI structural markers associated with cognitive impairment in these subgroups. Methods: Baseline data from the French multicentric PREDISTIM cohort were used. Candidates to STN-DBS were classified according to their cognitive performance in normal cognition (PD-NC) or PD-MCI. The latter included frontostriatal (PD-FS) and posterior cortical (PD-PC) subtypes. Between-group comparisons were performed on demographical and clinical variables as well as on T1-weighted MRI sequences at the cortical and subcortical levels. Results: 320 patients were included: 167 (52%) PD-NC and 153 (48%) PD-MCI patients. The latter group included 123 (80%) PD-FS and 30 (20%) PD-PC patients. There was no between-group difference regarding demographic and clinical variables. PD-PC patients had significantly lower global efficiency than PD-FS patients and significantly worse performance on visuospatial functions, episodic memory, and language. Compared to PD-NC, PD-MCI patients had cortical thinning and radiomic-based changes in the left caudate nucleus and hippocampus. There were no significant differences between the PD-MCI subtypes. Conclusion: Among the candidates to STN-DBS, a significant proportion has PD-MCI which is associated with cortical and subcortical alterations. Some PD-MCI patients have posterior cortical deficits, a subtype known to be at higher risk of dementia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Limbic Stimulation Drives Mania in STN‐DBS in Parkinson Disease: A Prospective Study.
- Author
-
Prange, Stéphane, Lin, Zhengyu, Nourredine, Mikail, Danaila, Teodor, Laurencin, Chloé, Lagha‐Boukbiza, Ouhaid, Anheim, Mathieu, Klinger, Hélène, Longato, Nadine, Phillipps, Clelie, Voirin, Jimmy, Polo, Gustavo, Simon, Emile, Mertens, Patrick, Rolland, Anne‐Sophie, Devos, David, Metereau, Elise, Tranchant, Christine, Thobois, Stéphane, and Moreau, Caroline
- Abstract
In this one‐year prospective study, Parkinson's disease (PD) patients with or without mania following STN‐DBS were compared to investigate risk and etiological factors, clinical management and consequences. Eighteen (16.2%) out of 111 consecutive PD patients developed mania, of whom 17 were males. No preoperative risk factor was identified. Postoperative mania was related to ventral limbic subthalamic stimulation in 15 (83%) patients, and resolved as stimulation was relocated to the sensorimotor STN, besides discontinuation or reduction of dopamine agonists and use of low‐dose clozapine in 12 patients, while motor and nonmotor outcomes were similar. These findings underpin the prominent role of limbic subthalamic stimulation in postoperative mania. ANN NEUROL 2022;92:411–417 [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Internal Pallidum and Substantia Nigra Control Different Parts of the Mesopontine Reticular Formation in Primate
- Author
-
Rolland, Anne-Sophie, Karachi, Carine, Muriel, Marie-Paule, Hirsch, Etienne C., and François, Chantal
- Published
- 2011
- Full Text
- View/download PDF
23. Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations
- Author
-
Mangone, Graziella, primary, Bekadar, Samir, additional, Cormier-Dequaire, Florence, additional, Tahiri, Khadija, additional, Welaratne, Arlette, additional, Czernecki, Virginie, additional, Pineau, Fanny, additional, Karachi, Carine, additional, Castrioto, Anna, additional, Durif, Frank, additional, Tranchant, Christine, additional, Devos, David, additional, Thobois, Stéphane, additional, Meissner, Wassilios G, additional, Navarro, Maria Soledad, additional, Cornu, Philippe, additional, Lesage, Suzanne, additional, Brice, Alexis, additional, Welter, Marie Laure, additional, Corvol, Jean-Christophe, additional, Benchetrit, Eve, additional, Delaby, Laure, additional, Berthet, Deborah, additional, Danjou, Fabrice, additional, Vidaihlet, Marie, additional, Krack, Paul, additional, Pelissier, Pierre, additional, Morand, Dominique, additional, Delaigue, Christine, additional, Barun, Nadia, additional, Anheim, Mathieu, additional, Pleuvret, Marie, additional, Destée, Alain, additional, Defebvre, Luc, additional, Moreau, Caroline, additional, Simonin, Clémence, additional, Ryckewaert, Gilles, additional, Kreisler, Alexandre, additional, Mutez, Eugénie, additional, Carrière, Nicolas, additional, Hopes, Lucie, additional, Tard, Céline, additional, Grolez, Guillaume, additional, Dujardin, Kathy, additional, Pecheux, Nathalie, additional, Delliaux, Marie, additional, Rolland, Anne-Sophie, additional, Broussolle, Emmanuel, additional, Laurencin, Chloè, additional, Tison, François, additional, and Burbaud, Pierre, additional
- Published
- 2020
- Full Text
- View/download PDF
24. Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease
- Author
-
Moreau, Caroline, primary, Rolland, Anne Sophie, additional, Pioli, Elsa, additional, Li, Qin, additional, Odou, Pascal, additional, Barthelemy, Christine, additional, Lannoy, Damien, additional, Demailly, Alexandre, additional, Carta, Natacha, additional, Deramecourt, Vincent, additional, Auger, Florent, additional, Kuchcinski, Gregory, additional, Laloux, Charlotte, additional, Defebvre, Luc, additional, Bordet, Regis, additional, Duce, James, additional, Devedjian, Jean Christophe, additional, Bezard, Erwan, additional, Fisichella, Matthieu, additional, and Devos, David, additional
- Published
- 2020
- Full Text
- View/download PDF
25. Intérêt des semelles connectées dans l’évaluation de la marche dans la maladie de Parkinson
- Author
-
Moreau, Caroline, primary, Farid, Leila, additional, Rolland, Anne-Sophie, additional, Baille, Guillaume, additional, Jacobs, Damien, additional, Bezard, Erwan, additional, Defebvre, Luc, additional, Delval, Arnaud, additional, Devos, David, additional, and Guehl, Dominique, additional
- Published
- 2019
- Full Text
- View/download PDF
26. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication
- Author
-
Rolland, Anne-Sophie, Tandé, Dominique, Herrero, Maria-Trinidad, Luquin, Maria-Rosario, Vazquez-Claverie, Marianne, Karachi, Carine, Hirsch, Etienne C, and François, Chantal
- Published
- 2009
- Full Text
- View/download PDF
27. Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates
- Author
-
Gouel, Flore, Rolland, Anne-Sophie, Devedjian, Jean-Christophe, Burnouf, Thierry, and Devos, David
- Subjects
stem cell ,therapeutic ,Neurology ,human platelet lysate ,Mini Review ,growth factors ,Neurology (clinical) ,Amyotrophic lateral sclerosis - Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3-5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capacities in the central nervous system-e.g., development, plasticity, maintenance, neurogenesis-neurotrophic growth factors (NTF) have been exploited for therapeutic strategies in ALS for decades. In this review we present the initial strategy of using single NTF by different routes of administration to the use of stem cells transplantation to express a multiple NTFs-rich secretome to finally focus on a new biotherapy based on the human platelet lysates, the natural healing system containing a mix of pleitropic NTF and having immunomodulatory function. This review highlights that this latter treatment may be crucial to power the neuroprotection and/or neurorestoration therapy requested in this devastating disease.
- Published
- 2019
- Full Text
- View/download PDF
28. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism
- Author
-
Rolland, Anne-Sophie, Herrero, Maria-Trinidad, Garcia-Martinez, Virginia, Ruberg, Merle, Hirsch, Etienne C., and François, Chantal
- Published
- 2007
29. Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study.
- Author
-
Santin, Marie des Neiges, Voulleminot, Paul, Vrillon, Agathe, Hainque, Elodie, Béreau, Matthieu, Lagha‐Boukbiza, Ouhaid, Wirth, Thomas, Montaut, Solveig, Bardinet, Eric, Kyheng, Maeva, Rolland, Anne‐Sophie, Voirin, Jimmy, Drapier, Sophie, Durif, Franck, Eusebio, Alexandre, Giordana, Caroline, Auzou, Nicolas, Houeto, Jean‐Luc, Hubsch, Cécile, and Jarraya, Béchir
- Abstract
Background: Impact of subthalamic deep brain stimulation (DBS) on impulse control disorders (ICD) in Parkinson's disease (PD) remains controversial. Objectives: The objectives of this study were to analyze the natural history of ICD between baseline and 1 year after subthalamic DBS in patients with PD and to identify predictive factors, taking into account the positions of the active contact and stimulation parameters. Methods: We analyzed postoperative modifications of ICD based on the multicentric, prospective Predictive Factors and Subthalamic Stimulation in Parkinson's Disease cohort. ICD status and Ardouin Scale of Behaviour in PD were assessed at baseline and 1 year following subthalamic DBS. Location of active contacts within the 3 subthalamic nucleus functional territories was investigated. Results: A total of 217 were patients included. Of the patients, 10.6% had ICD at baseline of which 95.6% improved at 1 year following subthalamic DBS; 3.6% of the patients experienced de novo ICD at 1 year following subthalamic DBS. Dopamine agonist dose reduction (from 309.8 to 109.3 mg) was the main driver of ICD regression (P = 0.05). Higher preoperative dyskinesias were associated with poorer ICD evolution (P = 0.04). Whereas baseline apathy was a risk factor of de novo ICD (P = 0.02), ICD improvement correlated with postoperative apathy (P = 0.004). Stimulation power and position of active contacts—mainly located within the sensorimotor part of the subthalamic nucleus—did not influence ICD. Conclusions: This 1‐year, postoperative follow‐up study showed ICD regression and dopaminergic drug reduction with optimal position of the active contacts within the subthalamic nucleus. Whereas patients with PD with preoperative ICD were prone to postoperative apathy, we also showed that those with preoperative apathy had a higher risk to experience postoperative de novo ICD, further highlighting the meaningful influence of postoperative management of dopaminergic medication on outcome and the continuum between apathy and ICD. © 2020 International Parkinson and Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration
- Author
-
Masaldan, Shashank, primary, Bush, Ashley I., additional, Devos, David, additional, Rolland, Anne Sophie, additional, and Moreau, Caroline, additional
- Published
- 2019
- Full Text
- View/download PDF
31. Post mortem high resolution diffusion MRI for large specimen imaging at 11.7 T with 3D segmented echo-planar imaging
- Author
-
Sébille, Sophie Bernadette, primary, Rolland, Anne-Sophie, additional, Welter, Marie-Laure, additional, Bardinet, Eric, additional, and Santin, Mathieu David, additional
- Published
- 2019
- Full Text
- View/download PDF
32. Normal and pathological neuronal distribution of the human mesencephalic locomotor region.
- Author
-
Sébille, Sophie B., Rolland, Anne‐Sophie, Faillot, Matthieu, Perez‐Garcia, Fernando, Colomb‐Clerc, Antoine, Lau, Brian, Dumas, Sylvie, Vidal, Sara Fernandez, Welter, Marie‐Laure, Francois, Chantal, Bardinet, Eric, Karachi, Carine, Rolland, Anne-Sophie, Perez-Garcia, Fernando, Colomb-Clerc, Antoine, and Welter, Marie-Laure
- Subjects
- *
BRAIN stem , *COMPARATIVE studies , *DIGITAL image processing , *RESEARCH methodology , *MEDICAL cooperation , *NEURONS , *PARKINSON'S disease , *PROGRESSIVE supranuclear palsy , *RESEARCH , *RESEARCH funding , *EVALUATION research , *DEEP brain stimulation - Abstract
Background: Deep brain stimulation of the pedunculopontine nucleus has been performed to treat dopamine-resistant gait and balance disorders in patients with degenerative diseases. The outcomes, however, are variable, which may be the result of the lack of a well-defined anatomical target.Objectives: The objectives of this study were to identify the main neuronal populations of the pedunculopontine and the cuneiform nuclei that compose the human mesencephalic locomotor region and to compare their 3-dimensional distribution with those found in patients with Parkinson's disease and progressive supranuclear palsy.Methods: We used high-field MRI, immunohistochemistry, and in situ hybridization to characterize the distribution of the different cell types, and we developed software to merge all data within a common 3-dimensional space.Results: We found that cholinergic, GABAergic, and glutamatergic neurons comprised the main cell types of the mesencephalic locomotor region, with the peak densities of cholinergic and GABAergic neurons similarly located within the rostral pedunculopontine nucleus. Cholinergic and noncholinergic neuronal losses were homogeneous in the mesencephalic locomotor region of patients, with the peak density of remaining neurons at the same location as in controls. The degree of denervation of the pedunculopontine nucleus was highest in patients with progressive supranuclear palsy, followed by Parkinson's disease patients with falls.Conclusions: The peak density of cholinergic and GABAergic neurons was located similarly within the rostral pedunculopontine nucleus not only in controls but also in pathological cases. The neuronal loss was homogeneously distributed and highest in the pedunculopontine nucleus of patients with falls, which suggests a potential pathophysiological link. © 2018 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
33. Normal and pathological neuronal distribution of the human mesencephalic locomotor region
- Author
-
Sébille, Sophie B., primary, Rolland, Anne‐Sophie, additional, Faillot, Matthieu, additional, Perez‐Garcia, Fernando, additional, Colomb‐Clerc, Antoine, additional, Lau, Brian, additional, Dumas, Sylvie, additional, Vidal, Sara Fernandez, additional, Welter, Marie‐Laure, additional, Francois, Chantal, additional, Bardinet, Eric, additional, and Karachi, Carine, additional
- Published
- 2018
- Full Text
- View/download PDF
34. Preoperative REM Sleep Behavior Disorder and Subthalamic Nucleus Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery
- Author
-
Besse-Pinot, Elsa, Pereira, Bruno, Durif, Franck, Fantini, Maria Livia, Durand, Elodie, Debilly, Bérengère, Derost, Philippe, Moreau, Caroline, Hainque, Elodie, Rouaud, Tiphaine, Eusebio, Alexandre, Benatru, Isabelle, Drapier, Sophie, Guehl, Dominique, Rascol, Olivier, Maltête, David, Lagha-Boukbiza, Ouhaïd, Giordana, Caroline, Tir, Melissa, Thobois, Stéphane, Hopes, Lucie, Hubsch, Cécile, Jarraya, Béchir, Rolland, Anne-Sophie, Corvol, Jean-Christophe, Devos, David, and Marques, Ana
- Published
- 2021
- Full Text
- View/download PDF
35. Personality dimensions of patients can change during the course of parkinson's disease.
- Author
-
Boussac, Mathilde, Arbus, Christophe, Dupouy, Julia, Harroch, Estelle, Rousseau, Vanessa, Croiset, Aurélie, Ory-Magne, Fabienne, Rascol, Olivier, Moreau, Caroline, Rolland, Anne-Sophie, Maltête, David, Rouaud, Tiphaine, Meyer, Mylène, Drapier, Sophie, Giordana, Bruno, Anheim, Mathieu, Hainque, Elodie, Jarraya, Béchir, Benatru, Isabelle, and Auzou, Nicolas
- Subjects
PARKINSON'S disease ,DEEP brain stimulation ,DOPAMINERGIC neurons ,PERSONALITY ,PERSONALITY studies - Abstract
Background: Studies assessing personality dimensions by the "Temperament and Character Inventory" (TCI) have previously found an association between Parkinson's disease (PD) and lower Novelty Seeking and higher Harm Avoidance scores. Here, we aimed to describe personality dimensions of PD patients with motor fluctuations and compare them to a normative population and other PD populations. Methods: All PD patients awaiting Deep Brain Stimulation (DBS) answered the TCI before neurosurgery. Their results were compared to those of historical cohorts (a French normative population, a de novo PD population, and a PD population with motor fluctuations). Results: Most personality dimensions of our 333 included PD patients with motor fluctuations who are candidates for DBS were different from those of the normative population and some were also different from those of the De Novo PD population, whereas they were similar to those of another population of PD patients with motor fluctuations. Conclusions: During the course of PD, personality dimensions can change in parallel with the development of motor fluctuations, either due to the evolution of the disease and/or dopaminergic treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
- Author
-
Devos, David, Cabantchik, Z. Ioav, Moreau, Caroline, Danel, Véronique, Mahoney-Sanchez, Laura, Bouchaoui, Hind, Gouel, Flore, Rolland, Anne-Sophie, Duce, James A., Devedjian, Jean-Christophe, The FAIRPARK-II and FAIRALS-II studygroups, Cassereau, Julien, Bost, Marie, Abrial, Charlotte, Muller, Jeanne, Olivier, Audrey, Le Masson, Gwendal, Mathis, Stéphane, Djigo, Dieynaba, and Bonabaud, Sarah
- Subjects
AMYOTROPHIC lateral sclerosis ,DEFEROXAMINE ,PARKINSON'S disease ,FERRITIN ,NEURODEGENERATION ,FRONTOTEMPORAL lobar degeneration ,CHELATION ,EFFERENT pathways ,BLEPHAROPTOSIS - Abstract
Focal iron accumulation associated with brain iron dyshomeostasis is a pathological hallmark of various neurodegenerative diseases (NDD). The application of iron-sensitive sequences in magnetic resonance imaging has provided a useful tool to identify the underlying NDD pathology. In the three major NDD, degeneration occurs in central nervous system (CNS) regions associated with memory (Alzheimer's disease, AD), automaticity (Parkinson's disease, PD) and motor function (amyotrophic lateral sclerosis, ALS), all of which require a high oxygen demand for harnessing neuronal energy. In PD, a progressive degeneration of the substantia nigra pars compacta (SNc) is associated with the appearance of siderotic foci, largely caused by increased labile iron levels resulting from an imbalance between cell iron import, storage and export. At a molecular level, α-synuclein regulates dopamine and iron transport with PD-associated mutations in this protein causing functional disruption to these processes. Equally, in ALS, an early iron accumulation is present in neurons of the cortico-spinal motor pathway before neuropathology and secondary iron accumulation in microglia. High serum ferritin is an indicator of poor prognosis in ALS and the application of iron-sensitive sequences in magnetic resonance imaging has become a useful tool in identifying pathology. The molecular pathways that cascade down from such dyshomeostasis still remain to be fully elucidated but strong inroads have been made in recent years. Far from being a simple cause or consequence, it has recently been discovered that these alterations can trigger susceptibility to an iron-dependent cell-death pathway with unique lipoperoxidation signatures called ferroptosis. In turn, this has now provided insight into some key modulators of this cell-death pathway that could be therapeutic targets for the NDD. Interestingly, iron accumulation and ferroptosis are highly sensitive to iron chelation. However, whilst chelators that strongly scavenge intracellular iron protect against oxidative neuronal damage in mammalian models and are proven to be effective in treating systemic siderosis, these compounds are not clinically suitable due to the high risk of developing iatrogenic iron depletion and ensuing anaemia. Instead, a moderate iron chelation modality that conserves systemic iron offers a novel therapeutic strategy for neuroprotection. As demonstrated with the prototype chelator deferiprone, iron can be scavenged from labile iron complexes in the brain and transferred (conservatively) either to higher affinity acceptors in cells or extracellular transferrin. Promising preclinical and clinical proof of concept trials has led to several current large randomized clinical trials that aim to demonstrate the efficacy and safety of conservative iron chelation for NDD, notably in a long-term treatment regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. A quantitative evaluation of a 2.5-kb rat tyrosine hydroxylase promoter to target expression in ventral mesencephalic dopamine neurons in vivo
- Author
-
Rolland, Anne-Sophie, primary, Kareva, Tatyana, additional, Kholodilov, Nikolai, additional, and Burke, Robert E., additional
- Published
- 2017
- Full Text
- View/download PDF
38. Expression mediated by three partial sequences of the human tyrosine hydroxylase promoter in vivo
- Author
-
Rolland, Anne-Sophie, primary, Kareva, Tatyana, additional, Yarygina, Olga, additional, Kholodilov, Nikolai, additional, and Burke, Robert E, additional
- Published
- 2016
- Full Text
- View/download PDF
39. A Dual Role of Adenosine A2AReceptors in 3-Nitropropionic Acid-Induced Striatal Lesions: Implications for the Neuroprotective Potential of A2AAntagonists
- Author
-
Blum, David, primary, Galas, Marie-Christine, additional, Pintor, Annita, additional, Brouillet, Emmanuel, additional, Ledent, Catherine, additional, Muller, Christa E., additional, Bantubungi, Kadiombo, additional, Galluzzo, Mariangela, additional, Gall, David, additional, Cuvelier, Laetitia, additional, Rolland, Anne-Sophie, additional, Popoli, Patrizia, additional, and Schiffmann, Serge N., additional
- Published
- 2003
- Full Text
- View/download PDF
40. Thalamic Neuronal Activity in Dopamine-Depleted Primates: Evidence for a Loss of Functional Segregation within Basal Ganglia Circuits.
- Author
-
Pessiglione, Mathias, Rolland, Anne-Sophie, François, Chantal, Hirsch, Etienne C., Féger, Jean, Tremblay, Léon, and Guehl, Dominique
- Subjects
- *
NEURONS , *PARKINSON'S disease , *BRAIN diseases , *DOPAMINE , *BASAL ganglia , *CERCOPITHECUS - Abstract
Different analyses of neuronal activity in primate models of Parkinson's disease (PD) have resulted in two different views on the effects of dopamine depletion. The first is based on the higher firing rate and bursty firing pattern, and assumes that dopamine depletion results in a hyperactivity of basal ganglia (BG) output structures. The second is based on the less-specific responses to passive joint manipulation and the excessive correlations between neuronal discharges, and assumes that dopamine depletion results in a loss of functional segregation in cortico-BG circuits. The aim of the present study was to test out the predictions of these two different views on thalamic neuronal activity. Three male vervet monkeys (Cercopithecus aethiops) were progressively intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuronal activities were characterized using standard analyses (firing rates and patterns, receptive fields, and cross-correlations) and compared between the normal, asymptomatic (before the stabilization of motor symptoms), and parkinsonian (with persistent akinesia and rigidity) stages of MPTP intoxication. The pallidonigral thalamus (receiving projections from the BG) was characterized in both the asymptomatic and parkinsonian states by (1) an unchanged firing rate and pattern and (2) a proliferation of nonspecific neurons and correlated pairs. In contrast, the cerebellar thalamus (receiving projections from the cerebellum), was characterized by no change (asymptomatic state) or minor changes (symptomatic state). Thus the major dysfunction after dopamine depletion appeared to be the loss of functional segregation within cortico-BG circuits, which could also be at the heart of parkinsonian pathophysiology. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
41. A Dual Role of Adenosine A[sub2A] Receptors in 3-Nitropropionic Acid-Induced Striatal Lesions: Implications for the Neuroprotective Potential of A[sub2A] Antagonists.
- Author
-
Blum, David, Galas, Marie-Christine, Pintor, Annita, Brouillet, Emmanuel, Ledent, Catherine, Muller, Christa E., Bantubungi, Kadiombo, Galluzzo, Mariangela, Gall, David, Cuvelier, Laetitia, Rolland, Anne-Sophie, Popoli, Patrizia, and Schiffmann, Serge N.
- Subjects
ADENOSINES ,PROPIONIC acid ,HUNTINGTON disease ,NEURODEGENERATION - Abstract
Reduction of A[sub2A] receptor expression is one of the earliest events occurring in both Huntington's disease (HD) patients and mice overexpressing the N-terminal part of mutated huntingtin. Interestingly, increased activity of A[sub2A] receptors has been found in striatal cells prone to degenerate in experimental models of this neurodegenerative disease. However, the role of A[sub2A] receptors in the pathogenesis of HD remains obscure. In the present study, using A[sub2A][sup-/-] mice and pharmacological compounds in rat, we demonstrate that striatal neurodegeneration induced by the mitochondrial toxin 3-nitropropionic acid (3NP) is regulated by A[sub2A] receptors. Our results show that the striatal outcome induced by 3NP depends on a balance between the deleterious activity of presynaptic A[sub2A] receptors and the protective activity of postsynaptic A[sub2A] receptors. Moreover, microdialysis data demonstrate that this balance is anatomically determined, because the A[sub2A] presynaptic control on striatal glutamate release is absent within the posterior striatum. Therefore, because blockade of A[sub2A] receptors has differential effects on striatal cell death in vivo depending on its ability to modulate presynaptic over postsynaptic receptor activity, therapeutic use of A[sub2A] antagonists in Huntington's as well as in other neurodegenerative diseases could exhibit undesirable biphasic neuroprotective-neurotoxic effects. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
42. Personality assessment with Temperament and Character Inventory in Parkinson's disease.
- Author
-
Boussac, Mathilde, Arbus, Christophe, Colin, Olivier, Laurencin, Chloé, Eusebio, Alexandre, Hainque, Elodie, Corvol, Jean Christophe, Versace, Nathalie, Rascol, Olivier, Rousseau, Vanessa, Harroch, Estelle, Ory-Magne, Fabienne, Fabbri, Margherita, Moreau, Caroline, Rolland, Anne-Sophie, Jarraya, Béchir, Maltête, David, Drapier, Sophie, Marques, Ana-Raquel, and Auzou, Nicolas
- Abstract
Introduction: There is a growing interest in personality evaluation in Parkinson's disease (PD), following observations of specific temperaments in PD patients. Therefore, our objective was to evaluate personality dimensions from the Temperament and Character Inventory (TCI) in a cohort of fluctuating PD patients considered for deep brain stimulation.Methods: Fluctuating PD patients from the PREDISTIM cohort were included. Description of TCI dimensions and comparison with a French normative cohort were performed. Pearson correlations between TCI dimensions and motor, behavioral and cognitive variables were investigated. Structural and internal consistency analysis of the TCI were further assessed.Results: The 570 PD patients presented significant higher scores in Harm Avoidance, Reward Dependence, Persistence, Self-Directedness and Cooperativeness and significant lower scores in Self-Transcendence compared to the French normative cohort; only Novelty Seeking scores were not different. Harm Avoidance and Self-directedness scores were correlated with PDQ-39 total, HAMD, HAMA scores, and anxiolytic/antidepressant treatment. Novelty Seeking scores were correlated with impulsivity. Pearson correlations between TCI dimensions, principal component analysis of TCI sub-dimensions and Cronbach's alpha coefficients showed adequate psychometric proprieties.Conclusion: The TCI seems to be an adequate tool to evaluate personality dimensions in PD with good structural and internal consistencies. These fluctuating PD patients also have specific personality dimensions compared to normative French population. Moreover, Harm Avoidance and Self-Directedness scores are associated with anxio-depressive state or quality of life and, and Novelty Seeking scores with impulsivity. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
43. Assessing the upper motor neuron in amyotrophic lateral sclerosis using the triple stimulation technique: A multicenter prospective study.
- Author
-
Grapperon, Aude-Marie, Verschueren, Annie, Jouve, Elisabeth, Morizot-Koutlidis, Régine, Lenglet, Timothée, Pradat, Pierre-François, Salachas, François, Bernard, Emilien, Delstanche, Stéphanie, Maertens de Noordhout, Alain, Guy, Nathalie, Danel, Véronique, Delval, Arnaud, Delmont, Emilien, Rolland, Anne-Sophie, PULSE Study Group, Jomir, Laurent, Devos, David, Wang, François, and Attarian, Shahram
- Subjects
- *
AMYOTROPHIC lateral sclerosis , *MOTOR neurons , *TRANSCRANIAL magnetic stimulation , *LONGITUDINAL method , *MOTOR unit - Abstract
• - Triple stimulation technique can be used in routine clinical practice and in multicenter studies in ALS patients. • - Assessment of corticospinal dysfunction at the first visit of the patient was improved by the use of triple stimulation technique compared to conventional TMS. • - Triple stimulation technique results are correlated with the clinical upper motor neuron score and ALSFRS-R. To evaluate the relevance of transcranial magnetic stimulation (TMS) using triple stimulation technique (TST) to assess corticospinal function in amyotrophic lateral sclerosis (ALS) in a large-scale multicenter study. Six ALS centers performed TST and conventional TMS in upper limbs in 98 ALS patients during their first visit to the center. Clinical evaluation of patients included the revised ALS Functional Rating Scale (ALSFRS-R) and upper motor neuron (UMN) score. TST amplitude ratio was decreased in 62% of patients whereas conventional TMS amplitude ratio was decreased in 25% of patients and central motor conduction time was increased in 16% of patients. TST amplitude ratio was correlated with ALSFRS-R and UMN score. TST amplitude ratio results were not different between the centers. TST is a TMS technique applicable in daily clinical practice in ALS centers for the detection of UMN dysfunction, more sensitive than conventional TMS and related to the clinical condition of the patients. This multicenter study shows that TST can be a routine clinical tool to evaluate UMN dysfunction at the diagnostic assessment of ALS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
44. ON/OFF non-motor evaluation: a new way to evaluate non-motor fluctuations in Parkinson's disease.
- Author
-
Faggianelli F, Witjas T, Azulay JP, Benatru I, Hubsch C, Anheim M, Moreau C, Hainque E, Drapier S, Jarraya B, Laurencin C, Guehl D, Hopes L, Brefel-Courbon C, Tir M, Marques A, Rouaud T, Maltete D, Giordana C, Baumstarck K, Rascol O, Corvol JC, Rolland AS, Devos D, and Eusebio A
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Surveys and Questionnaires, Severity of Illness Index, Subthalamic Nucleus physiopathology, Parkinson Disease physiopathology, Parkinson Disease drug therapy, Parkinson Disease complications, Levodopa therapeutic use, Deep Brain Stimulation, Antiparkinson Agents therapeutic use
- Abstract
Background: NMF are currently poorly evaluated in therapeutic decisions. A quantification of their severity would facilitate their integration. The objective of this study was to validate an autoquestionnaire evaluating the severity of non-motor fluctuations (NMF) in Parkinson's disease (PD)., Methods: Patients with PD were included in presurgical situation for deep brain stimulation of subthalamic nuclei. They participated in the PREDISTIM cohort (a study evaluating the predictive factors for therapeutic response of subthalamic stimulation in PD) in 17 centres in France. Our questionnaire, resulting from previous phases of development, included 11 non-motor symptoms (NMS). Their severity ranged from 0 to 10 and was assessed in OFF and then ON-Dopa to study their fluctuations., Results: 310 patients were included, of whom 98.8% had NMS and 98.0% had NMF. Each NMS was significantly improved by L-Dopa (decrease in severity score ranging from 43.1% to 69.9%). Fatigue was the most frequent and most severe NMS. NMS were considered more bothersome than motor symptoms by 37.5% of patients in OFF-Dopa and 34.9% in ON-Dopa., Conclusions: This is the first questionnaire allowing a real-time quantification of the severity of NMS and their fluctuation with levodopa. It was able to confirm and measure the effect of L-dopa and show differences according to the patients and the NMS. It differs from other questionnaires by its measurement at a precise moment of the severity of the NMS, allowing its use during pretherapeutic assessments.Our questionnaire has been validated to measure the severity of NMF. It will be able to quantify the non-motor effect of anti-parkinsonian treatments and could facilitate the integration of NMF in therapeutic decisions., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
45. Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson's disease.
- Author
-
Béreau M, Kibleur A, Servant M, Clément G, Dujardin K, Rolland AS, Wirth T, Lagha-Boukbiza O, Voirin J, Santin MDN, Hainque E, Grabli D, Comte A, Drapier S, Durif F, Marques A, Eusebio A, Azulay JP, Giordana C, Houeto JL, Jarraya B, Maltete D, Rascol O, Rouaud T, Tir M, Moreau C, Danaila T, Prange S, Tatu L, Tranchant C, Corvol JC, Devos D, Thobois S, Desmarets M, and Anheim M
- Subjects
- Humans, Prospective Studies, Cognition, Treatment Outcome, Parkinson Disease complications, Subthalamic Nucleus physiology, Apathy physiology, Deep Brain Stimulation methods
- Abstract
Postoperative apathy is a frequent symptom in Parkinson's disease patients who have undergone bilateral deep brain stimulation of the subthalamic nucleus. Two main hypotheses for postoperative apathy have been suggested: (i) dopaminergic withdrawal syndrome relative to postoperative dopaminergic drug tapering; and (ii) direct effect of chronic stimulation of the subthalamic nucleus. The primary objective of our study was to describe preoperative and 1-year postoperative apathy in Parkinson's disease patients who underwent chronic bilateral deep brain stimulation of the subthalamic nucleus. We also aimed to identify factors associated with 1-year postoperative apathy considering: (i) preoperative clinical phenotype; (ii) dopaminergic drug management; and (iii) volume of tissue activated within the subthalamic nucleus and the surrounding structures. We investigated a prospective clinical cohort of 367 patients before and 1 year after chronic bilateral deep brain stimulation of the subthalamic nucleus. We assessed apathy using the Lille Apathy Rating Scale and carried out a systematic evaluation of motor, cognitive and behavioural signs. We modelled the volume of tissue activated in 161 patients using the Lead-DBS toolbox and analysed overlaps within motor, cognitive and limbic parts of the subthalamic nucleus. Of the 367 patients, 94 (25.6%) exhibited 1-year postoperative apathy: 67 (18.2%) with 'de novo apathy' and 27 (7.4%) with 'sustained apathy'. We observed disappearance of preoperative apathy in 22 (6.0%) patients, who were classified as having 'reversed apathy'. Lastly, 251 (68.4%) patients had neither preoperative nor postoperative apathy and were classified as having 'no apathy'. We identified preoperative apathy score [odds ratio (OR) 1.16; 95% confidence interval (CI) 1.10, 1.22; P < 0.001], preoperative episodic memory free recall score (OR 0.93; 95% CI 0.88, 0.97; P = 0.003) and 1-year postoperative motor responsiveness (OR 0.98; 95% CI 0.96, 0.99; P = 0.009) as the main factors associated with postoperative apathy. We showed that neither dopaminergic dose reduction nor subthalamic stimulation were associated with postoperative apathy. Patients with 'sustained apathy' had poorer preoperative fronto-striatal cognitive status and a higher preoperative action initiation apathy subscore. In these patients, apathy score and cognitive status worsened postoperatively despite significantly lower reduction in dopamine agonists (P = 0.023), suggesting cognitive dopa-resistant apathy. Patients with 'reversed apathy' benefited from the psychostimulant effect of chronic stimulation of the limbic part of the left subthalamic nucleus (P = 0.043), suggesting motivational apathy. Our results highlight the need for careful preoperative assessment of motivational and cognitive components of apathy as well as executive functions in order to better prevent or manage postoperative apathy., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
46. Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson's Disease (PSYCHO-STIM II).
- Author
-
Boussac M, Arbus C, Klinger H, Eusebio A, Hainque E, Corvol JC, Rascol O, Rousseau V, Harroch E, d'Apollonia CS, Croiset A, Ory-Magne F, De Barros A, Fabbri M, Moreau C, Rolland AS, Benatru I, Anheim M, Marques AR, Maltête D, Drapier S, Jarraya B, Hubsch C, Guehl D, Meyer M, Rouaud T, Giordana B, Tir M, Devos D, and Brefel-Courbon C
- Subjects
- Cohort Studies, Humans, Personality, Quality of Life, Deep Brain Stimulation methods, Parkinson Disease surgery, Parkinson Disease therapy, Subthalamic Nucleus physiology
- Abstract
Background: Deep brain stimulation of the sub-thalamic nucleus (DBS-STN) reduces symptoms in Parkinson's disease (PD) patients with motor fluctuations. However, some patients may not feel ameliorated afterwards, despite an objective motor improvement. It is thus important to find new predictors of patients' quality of life (QoL) amelioration after DBS-STN. We hypothesized that personality dimensions might affect QoL after DBS-STN., Objective: To evaluate associations between personality dimensions and QoL improvement one year after DBS-STN., Methods: DBS-STN-PD patients (n = 303) having answered the "Temperament and Character Inventory" (TCI) before surgery and the PDQ-39 before and one year after surgery were included, from the cohort study PREDI-STIM. Linear regression models were used to evaluate associations between TCI dimensions and change in PDQ-39 scores after DBS-STN., Results: Novelty Seeking and Cooperativeness scores before surgery were positively associated with PDQ-39 scores improvement after DBS-STN (FDR-adjusted p < 0.01). Moreover, paradoxically unimproved patients with deterioration of their PDQ-39 scores after DBS-STN despite improvement of their MDS-UPDRS-IV scores had lower Cooperativeness scores, while paradoxically improved patients with amelioration of their PDQ-39 scores despite deterioration of their MDS-UPDRS-IV scores had higher Reward Dependence scores., Conclusion: Some presurgical personality dimensions were significantly associated with QoL amelioration and discrepancy between motor state and QoL changes after DBS-STN in PD. Educational programs before DBS-STN should take in account patient personality dimensions to better deal with their expectations.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.